http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014050742-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2842 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate | 2013-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_975ec93f728d4405a3996593217431d8 |
publicationDate | 2014-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2014050742-A1 |
titleOfInvention | Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject |
abstract | Methods of modulating the occurrence of lymphangiogenesis in a subject are provided. In some instances, the method is a method of treating transplant rejection in the subject. Aspects of the methods include administering to the subject an effective amount of: a first antagonist for a tyrosine kinase receptor and a second antagonist for an integrin receptor. In some embodiments, the methods include enhancing survival of transplanted tissue in a subject. Aspects of the invention further include compositions, e.g., pharmaceutical compositions and kits that find use in methods of the invention. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109982658-A |
priorityDate | 2012-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 67.